Novartis' Kisqali reduces breast cancer recurrence in early-stage patients.

Novartis' breast cancer drug Kisqali has reduced the risk of recurrence by over 25% in a pivotal trial on women diagnosed at an early stage. The drug was used in the trial together with standard endocrine therapy to treat a type of cancer that grows in response to hormones and it was compared to endocrine therapy alone. The drug has been approved to treat hormone-driven breast cancer that has spread to other parts of the body, where Novartis has taken market share from Pfizer's Ibrance. Novartis will request approval for wider use in the US and Europe before the end of the year.